In the latest twist to IL-6 roller coaster, Roche's Actemra fails PhIII Covid-19 Veklury combo trial
Roche is adding another tally mark to the negative column on Actemra’s mixed record in Covid-19.
The IL-6 drug failed to meet the primary endpoint …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
